While the United States undertakes sweeping revisions to its vaccination guidelines, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by questioning Covid shots during the global health crisis and has zeroed in on alleged deaths following COVID-19 vaccination in her brief position at the FDA.
Public health authorities were set to announce radical changes to the pediatric immunization program earlier this month, bringing the US with the Danish immunization schedule, it is understood – a major change that would put the US at odds with much of the international standard with insufficient data for benefit. The planned update has been postponed until the new year.
Rather than the top vaccines chief, Høeg is listed to address the audience at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to run the office this calendar year.
This interim role might represent a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a greater focus upon reevaluating long-standing vaccines at the FDA.
Dr. Høeg has frequently advocated for ending specific childhood vaccine recommendations in the US so as to align more similar to Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants roughly the population of Wisconsin’s.
So far public appearances, she has kept her attention on vaccines – typically the domain of Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.
Dr. Høeg has little discernible experience in pharmaceutical research, oversight or administrative roles, which has been standard for previous heads of the biologics center. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.
“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in running a large organization. She lacks background in industry regulation.”
Previous commissioners of CBER would “be deeply familiar with laws and regulations and the science of drug development”, noted Dr. Janet Woodcock. “Clearly, she lacks the kind of background that former directors who led the center have had.”
The drug center has an vast range of responsibilities at the agency, the former commissioner pointed out.
“The public just zeroes in on the innovative therapies, but the generic drug division approves numerous generic drugs. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one need to be looked after,” Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to bite you.”
Additionally, a major leadership component to the position, which manages more than 5,000 employees. “It is a enormous administrative position, if you perform it correctly,” she added.
When asked about concerns about Dr. Høeg's qualifications and whether this assignment indicates increased cooperation among regulatory chiefs on immunizations, a press secretary stated that the “concerns are based on incorrect assumptions”.
“Her resume matches the responsibilities of her job,” the official said, pointing to the time Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.
As the temporary head, Høeg inherits the agency head's controversial expedited review system, a controversial rapid medication authorization process that reportedly troubled her preceding directors. “By what process are these medications being chosen for this fast-track system? Who is making the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the FDA right now.”
Overall, he said, “the Food and Drug Administration appears to be shifting towards more relaxed rules of pharmaceuticals, with the exception of shots.”
Regarding vaccines, Dr. Høeg has a more established, if problematic, history, critics said. She released a research paper using non-validated volunteer-provided data to assess the rate of heart inflammation following COVID-19 immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are riskier than they are.
Among her “desired changes” for the current federal leadership included revising rules for recently developed shots and discontinuing “non-essential” immunizations, she said after the election on a podcast. At the agency, Dr. Høeg has allegedly floated the idea of preventing teenage boys from receiving COVID-19 vaccinations.
“She’s an thorough true believer who commences with her conclusions and tailors the evidence to fit the science in a very misleading, untruthful way,” Dr. Howard stated.
Dr. Høeg joined fellow contrarians, {like|
Elara is a passionate writer and photographer who shares insights on creativity and mindful living through engaging storytelling.
